Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus
- PMID: 17492591
- DOI: 10.1086/518250
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus
Abstract
The persistence of latently infected resting CD4+ T cells has been clearly demonstrated in human immunodeficiency virus (HIV)-infected individuals receiving effective antiviral therapy. However, estimates of the half-life of this viral reservoir have been quite divergent. We demonstrate clear evidence for decay of this HIV reservoir in patients who initiated antiviral therapy early in infection. The half-life of this latent viral reservoir was estimated to be 4.6 months. It is projected that it will take up to 7.7 years of continuous therapy to completely eliminate latently infected resting CD4+ T cells in infected individuals who initiate antiviral therapy early in HIV infection.
Comment in
-
Eliminating persistent HIV infection: getting to the end of the rainbow.J Infect Dis. 2007 Jun 15;195(12):1734-6. doi: 10.1086/518254. Epub 2007 May 2. J Infect Dis. 2007. PMID: 17492587 No abstract available.
Similar articles
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.J Clin Invest. 2005 Nov;115(11):3250-5. doi: 10.1172/JCI26197. J Clin Invest. 2005. PMID: 16276421 Free PMC article.
-
Latently infected cell activation: a way to reduce the size of the HIV reservoir?Bull Math Biol. 2012 Jul;74(7):1651-72. doi: 10.1007/s11538-012-9729-x. Epub 2012 May 5. Bull Math Biol. 2012. PMID: 22562387
-
The challenge of viral reservoirs in HIV-1 infection.Annu Rev Med. 2002;53:557-93. doi: 10.1146/annurev.med.53.082901.104024. Annu Rev Med. 2002. PMID: 11818490 Review.
-
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101. N Engl J Med. 1999. PMID: 10341272 Clinical Trial.
Cited by
-
HIV persistence: chemokines and their signalling pathways.Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):151-7. doi: 10.1016/j.cytogfr.2012.05.002. Epub 2012 Jun 28. Cytokine Growth Factor Rev. 2012. PMID: 22749173 Free PMC article. Review.
-
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8. doi: 10.1073/pnas.1120248109. Epub 2012 May 29. Proc Natl Acad Sci U S A. 2012. PMID: 22645358 Free PMC article.
-
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.J Infect Dis. 2013 Jun 1;207(11):1694-702. doi: 10.1093/infdis/jit086. Epub 2013 Mar 4. J Infect Dis. 2013. PMID: 23460751 Free PMC article.
-
Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.PLoS One. 2010 Jun 8;5(6):e10976. doi: 10.1371/journal.pone.0010976. PLoS One. 2010. PMID: 20544014 Free PMC article.
-
Understanding people who have never received HIV medical care: a population-based approach.Public Health Rep. 2010 Jul-Aug;125(4):520-7. doi: 10.1177/003335491012500406. Public Health Rep. 2010. PMID: 20597451 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials